FY2027 EPS Estimates for Journey Medical Cut by Analyst

Journey Medical Co. (NASDAQ:DERM) – B. Riley lowered their FY2027 earnings estimates for shares of Journey Medical in a report issued on Thursday, March 27th. B. Riley analyst K. Patel now anticipates that the company will earn $0.31 per share for the year, down from their prior forecast of $0.39. The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share.

Journey Medical (NASDAQ:DERM) last announced its earnings results on Wednesday, March 26th. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.30. Journey Medical had a negative net margin of 31.74% and a negative return on equity of 132.10%. The company had revenue of $14.30 million for the quarter, compared to analyst estimates of $14.21 million.

Separately, Alliance Global Partners reissued a “buy” rating on shares of Journey Medical in a research note on Thursday. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $9.67.

Journey Medical Stock Performance

DERM stock opened at $6.11 on Monday. The company has a 50 day moving average price of $5.09 and a 200 day moving average price of $5.17. Journey Medical has a fifty-two week low of $3.20 and a fifty-two week high of $6.89. The company has a debt-to-equity ratio of 1.81, a current ratio of 1.38 and a quick ratio of 1.03. The stock has a market capitalization of $127.64 million, a PE ratio of -6.50 and a beta of 0.97.

Institutional Investors Weigh In On Journey Medical

A number of institutional investors have recently made changes to their positions in DERM. Tang Capital Management LLC bought a new position in Journey Medical during the fourth quarter worth about $6,747,000. PVG Asset Management Corp increased its stake in shares of Journey Medical by 5.7% in the 3rd quarter. PVG Asset Management Corp now owns 167,545 shares of the company’s stock valued at $947,000 after acquiring an additional 9,005 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Journey Medical by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock valued at $613,000 after acquiring an additional 12,882 shares during the period. Citadel Advisors LLC bought a new position in Journey Medical during the 4th quarter worth approximately $174,000. Finally, Kovitz Investment Group Partners LLC grew its holdings in Journey Medical by 112.9% during the fourth quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company’s stock valued at $97,000 after purchasing an additional 13,105 shares during the period. 7.25% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Journey Medical

In other news, CEO Claude Maraoui sold 18,147 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $5.13, for a total value of $93,094.11. Following the transaction, the chief executive officer now owns 2,092,874 shares of the company’s stock, valued at $10,736,443.62. This represents a 0.86 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 105,831 shares of company stock worth $536,622 in the last quarter. 13.16% of the stock is owned by company insiders.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.